HCW Biologics Q2 Loss Widens, Warns of Going Concern Doubt
HCWB sits 77% above its 52-week low of $1.5 on light trading volume (0.1× avg).
Summary
HCW Biologics reported a wider Q2 net loss and warned of substantial doubt about its ability to continue as a going concern for at least 12 months without additional funding. The company posted a Q2 loss per share of $11.58. Revenue rose year-over-year on completion of a licensing agreement with Beijing Trimmune Biotech, but the company raised only $5.6 million in equity during the quarter. This follows a restatement of Q1 EPS from $2.19 to $1.39 due to a warrant accounting error and unremediated material weaknesses in internal controls. The going concern warning is a critical red flag for a company with a market cap under $5 million and a stock price around $2.66. Traders should note the company's urgent need for capital and the risk of further dilution or delisting.
At the time of this announcement, HCWB was trading at $2.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $1.50 to $44.10. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.